NASDAQ · CBUS
Healthcare · Biotechnology
$1.57
Up+$0.05 (+3.18%)
Updated Oct 8, 2026, 1:26 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CBUS
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
CBUS closed at $1.57 after 20 trading sessions, down 1.26% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $1.67 | $1.73 | $1.56 | $1.57 | 164.43K |
| Oct 5, 2026 | $1.72 | $1.77 | $1.65 | $1.68 | 231.4K |
| Oct 2, 2026 | $1.63 | $1.755 | $1.63 | $1.71 | 247.44K |
| Oct 1, 2026 | $1.63 | $1.64 | $1.58 | $1.63 | 106.4K |
| Sep 30, 2026 | $1.58 | $1.74 | $1.58 | $1.61 | 276.27K |
| Sep 29, 2026 | $1.49 | $1.63 | $1.35 | $1.55 | 270.25K |
| Sep 28, 2026 | $1.49 | $1.5186 | $1.39 | $1.47 | 103.04K |
| Sep 25, 2026 | $1.51 | $1.5394 | $1.48 | $1.52 | 66.79K |
| Sep 24, 2026 | $1.52 | $1.565 | $1.50 | $1.50 | 81.8K |
| Sep 23, 2026 | $1.60 | $1.66 | $1.53 | $1.54 | 46.37K |
| Sep 22, 2026 | $1.57 | $1.675 | $1.57 | $1.59 | 135.78K |
| Sep 21, 2026 | $1.61 | $1.6588 | $1.55 | $1.56 | 70.02K |
| Sep 18, 2026 | $1.60 | $1.665 | $1.56 | $1.61 | 139.15K |
| Sep 17, 2026 | $1.56 | $1.66 | $1.545 | $1.63 | 121.97K |
| Sep 16, 2026 | $1.58 | $1.58 | $1.48 | $1.51 | 115.03K |
| Sep 15, 2026 | $1.47 | $1.615 | $1.40 | $1.58 | 236.78K |
| Sep 14, 2026 | $1.54 | $1.62 | $1.48 | $1.49 | 132.95K |
| Sep 11, 2026 | $1.58 | $1.595 | $1.55 | $1.57 | 83.96K |
| Sep 10, 2026 | $1.56 | $1.61 | $1.56 | $1.585 | 68K |
| Sep 9, 2026 | $1.63 | $1.63 | $1.59 | $1.59 | 85.89K |
The latest Smart Investors Daily articles mentioning CBUS.
Company
Market Activity
Research & News
CBUS research
Company profile and research snapshot.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 25, 2026 | Jefferies | Hold | — |
| Dec 8, 2025 | Canaccord Genuity | Buy | — |
| May 12, 2025 | Canaccord Genuity | Buy | — |
| Mar 21, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 22, 2025 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Benzinga · Feb 6, 2026
Cibus to utilize proprietary Rapid Trait Development System™ to enable development of durable resistance to Light Leaf Spot disease, which has caused estimated yield losses of up to £300m in recent yearsSAN DIEGO,
Benzinga · Jan 29, 2026
Benzinga · Jan 29, 2026
The Company has also granted the underwriter a 30-day option to purchase up to an additional 1,999,999 shares of Class A Common Stock to cover over-allotments, if any. All shares of Class A Common Stock to be sold in the
Benzinga · Jan 28, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CBUS.
